Potential antitumor agents. 10. Synthesis and biochemical properties of 5-N-alkylamino-,N,N-dialkylamino-, and N-alkylacetamido-1-formylisoquinoline thiosemicarbazones.
D000818:Animals; D000970:Antineoplastic Agents / Q000138:chemical synthesis* / Q000494:pharmacology / Q000627:therapeutic use; D001665:Binding Sites; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy / Q000201:enzymology; D004273:DNA, Neoplasm / Q000096:biosynthesis; D003864:Depression, Chemical; D005260:Female; D005557:Formaldehyde / Q000138:chemical synthesis / Q000494:pharmacology / Q000627:therapeutic use; D066298:In Vitro Techniques; D007546:Isoquinolines / Q000138:chemical synthesis* / Q000494:pharmacology / Q000627:therapeutic use; D008113:Liver Neoplasms / Q000188:drug therapy / Q000201:enzymology; D051379:Mice; D008815:Mice, Inbred Strains; D009374:Neoplasms, Experimental / Q000188:drug therapy / Q000201:enzymology; D011485:Protein Binding; D012334:RNA, Neoplasm / Q000096:biosynthesis; D051381:Rats; D012262:Ribonucleoside Diphosphate Reductase / Q000037:antagonists & inhibitors / Q000378:metabolism; D012510:Sarcoma 180 / Q000188:drug therapy / Q000378:metabolism; D013329:Structure-Activity Relationship; D013882:Thiosemicarbazones / Q000138:chemical synthesis* / Q000494:pharmacology / Q000627:therapeutic use; D013936:Thymidine / Q000378:metabolism; D014316:Tritium; D014529:Uridine / Q000378:metabolism
D000970:Antineoplastic Agents; D004273:DNA, Neoplasm; D007546:Isoquinolines; D012334:RNA, Neoplasm; D013882:Thiosemicarbazones; D014316:Tritium; D005557:Formaldehyde; D012262:Ribonucleoside Diphosphate Reductase; D013936:Thymidine; D014529:Uridine